A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC.
NSCLC
antiangiogenic
bevacizumab
biomarkers
imaging
perfusion CT
tumor perfusion
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Nov 2021
06 Nov 2021
Historique:
received:
06
08
2021
revised:
29
10
2021
accepted:
03
11
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear. In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine the ability of pCT to detect early changes in blood flow (BF), blood volume (BV), and permeability (PMB), and to explore whether these changes could predict the response at day +42 in patients with advanced, treatment-naive, non-squamous NSCLC treated with cisplatin and gemcitabine plus bevacizumab. All of the perfusion parameters showed a consistent decrease during the course of treatment. The BV difference between baseline and early assessment was significant ( Our results confirm that pCT can capture early changes in tumor vasculature. A substantial early decline of BV from baseline might identify tumors less likely responsive to antiangiogenic-drugs.
Sections du résumé
BACKGROUND
BACKGROUND
The role of perfusion computed tomography (pCT) in detecting changes in tumor vascularization as part of a response to antiangiogenic therapy in non-small cell lung cancer (NSCLC) remains unclear.
METHODS
METHODS
In this prospective pilot study (IMPACT trial, NCT02316327), we aimed to determine the ability of pCT to detect early changes in blood flow (BF), blood volume (BV), and permeability (PMB), and to explore whether these changes could predict the response at day +42 in patients with advanced, treatment-naive, non-squamous NSCLC treated with cisplatin and gemcitabine plus bevacizumab.
RESULTS
RESULTS
All of the perfusion parameters showed a consistent decrease during the course of treatment. The BV difference between baseline and early assessment was significant (
CONCLUSIONS
CONCLUSIONS
Our results confirm that pCT can capture early changes in tumor vasculature. A substantial early decline of BV from baseline might identify tumors less likely responsive to antiangiogenic-drugs.
Identifiants
pubmed: 34771728
pii: cancers13215566
doi: 10.3390/cancers13215566
pmc: PMC8583202
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : F. Hoffmann-La Roche Ltd (Basel, Switzerland).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Radiol. 2013 Sep;86(1029):20120174
pubmed: 23908346
N Engl J Med. 2006 Dec 14;355(24):2542-50
pubmed: 17167137
Eur Radiol. 2019 Feb;29(2):915-923
pubmed: 30054795
J Vasc Res. 2010;47(6):481-93
pubmed: 20431297
Clin Transl Oncol. 2018 Jul;20(7):837-852
pubmed: 29256154
Clin Cancer Res. 2020 Jan 1;26(1):206-212
pubmed: 31558474
Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4258s-4262s
pubmed: 15217970
Eur Radiol. 2013 Aug;23(8):2127-36
pubmed: 23553586
J Clin Oncol. 2009 Mar 10;27(8):1227-34
pubmed: 19188680
Eur Radiol Exp. 2019 Jun 13;3(1):23
pubmed: 31197486
Radiology. 2018 Feb;286(2):685-695
pubmed: 29059037
J Thorac Oncol. 2015 Jan;10(1):164-71
pubmed: 25247342
Pharmacology. 2008;81(4):317-24
pubmed: 18322419
Cancer Res. 1997 Oct 15;57(20):4593-9
pubmed: 9377574
J Thorac Oncol. 2012 Jan;7(1):71-5
pubmed: 22011670
Phys Med Biol. 2016 Dec 21;61(24):8736-8749
pubmed: 27893446
Clin Cancer Res. 2019 Aug 15;25(16):4881-4887
pubmed: 30910855
J Comput Assist Tomogr. 2013 Jan-Feb;37(1):15-21
pubmed: 23321828
Blood. 2003 Jun 15;101(12):4878-86
pubmed: 12586633
Radiology. 2010 Dec;257(3):863-71
pubmed: 20843993
Cancer Res. 2005 Mar 15;65(6):2433-40
pubmed: 15781659
Radiology. 2011 May;259(2):574-82
pubmed: 21357523
Cancer Cell. 2012 Jan 17;21(1):82-91
pubmed: 22264790
Eur Radiol. 2010 Dec;20(12):2890-8
pubmed: 20625738
AJR Am J Roentgenol. 2009 Oct;193(4):1090-6
pubmed: 19770333